Asthma is a complex, heterogeneous disease with unmet treatment needs. Patients with severe asthma overall continue to have uncontrolled symptoms despite receiving controller therapies. This affects both type 2 and non–type 2 asthma patients.
Therapies that target IL-4, IL-5, and IL-13 are effective for many patients with type 2 disease but may not be effective for all. Currently, there are no available targeted therapies that benefit non–type 2 asthma patients.
Pulmonologist Dr Michael Wechsler, professor in the Department of Medicine at National Jewish Health, discusses recent advances that have guided the optimal use of available therapies and led to the development of new therapies for patients with severe asthma.
He discusses what happens to biomarkers of inflammation when specific pathways are targeted, and how that affects specific mechanisms of disease.
He also discusses emerging therapies that may benefit both type 2 and non–type 2 patients, including positive data from the NAVIGATOR, SOURCE, and CASCADE trials on the anti-TSLP drug tezepelumab, and developing therapies such as anti–IL-33, anti–IL-6, and anti–IL-17.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Advances in the Treatment of Adult Asthma - Medscape - May 27, 2021.
Comments